Physician profile
Pablo E Uribasterra
NPI 1912987405
$2,614.60
in general payments reported to CMS, 2019-2025
26 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $266 · 2021: $489 · 2022: $424 · 2023: $323 · 2024: $331 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.90 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.38 | 2019-2023 | Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $440.75 | 2019-2025 | |
| Hologic Sales and Service, LLC | $274.26 | 2019-2025 | Aptima |
| Astellas Pharma US INC | $194.63 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $175.61 | 2021-2024 | |
| Gynesonics, INC. | $156.72 | 2021 | |
| Coopersurgical, INC. | $102.53 | 2020-2024 | Paragard T 380a |
| Avion Pharmaceuticals | $97.00 | 2019-2020 | |
| Covidien LP | $82.77 | 2019 | |
| Pfizer INC. | $70.07 | 2022-2025 | |
| Axonics, INC. | $65.56 | 2023 | Axonics |
| Millicent US INC | $65.08 | 2025 | Intrarosa, Femring, Femlyv |
| Allergan, INC. | $51.44 | 2019 | |
| Myovant Sciences INC. | $46.61 | 2021-2022 | |
| Shield Therapeutics INC | $41.88 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $39.19 | 2019-2021 | |
| Agile Therapeutics, INC. | $24.00 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $22.50 | 2025 | |
| Vertical Pharmaceuticals, LLC | $21.23 | 2019 | |
| Duchesnay USA Incorporated | $20.94 | 2019 | |
| Mission Pharmacal Company | $20.05 | 2023 | Citranatal |
| Exeltis, USA INC. | $15.96 | 2024 | Slynd |
| Biogen, INC. | $15.87 | 2025 | Zurzuvae |
| Lupin INC. | $15.55 | 2020 | |
| Merck Sharp & Dohme LLC | $13.75 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Uribasterra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.